Production of virus and purification of viral envelope proteins for vaccine use
AssigneeConnaught Laboratories Limited
InventorsMary Elizabeth Ewasyshyn, Barry Ian Caplan, Anne-Marie Bonneau, Michel Henri Klein
Life of this patent
Estimating the term…
Abstract
Immunogenic envelope glycoproteins are produced from enveloped virus, such as of the paramyxoviridae family, particularly PIV-3 and RSV, by culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from the tissue culture, solubilizing the envelope glycoproteins and isolating the solubilized envelope glycoproteins by chromatography.
Claims10
A method of isolating a mixture of glycoproteins of a virus belonging to the paramyxoviridae family, which comprises:
- growing a virus belonging to the paramyxoviridae family and selected from the group consisting of respiratory syncytial virus (RSV) and parainfluenza virus (PIV), in a culture medium which is substantially free from exogenous growth factors and serum proteins on a cell substrate which is readily acceptable for use in human vaccine production,
- isolating the virus from said culture medium,
- solubilizing the glycoproteins from said isolated virus, and
- isolating and co-purifying said solubilized glycoproteins by affinity chromatography wherein the solubilized glycoproteins initially are bound to lentil-lectin or concanavilin A and subsequently eluted using a competing sugar.
A composition, comprising a co-purified mixture of viral envelope glycoproteins selected from the group consisting of a mixture of the HN and F glycoprotein of parainfluenza virus (PIV) and a mixture of the G and F glycoproteins of respiratory syncytial virus (RSV), and a carrier therefor.
Dependencies are inferred from the claim text.